Frontiers in immunology · 2024
Predictive biomarkers of mortality in patients with severe COVID-19 hospitalized in intensive care unit.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dos Santos Medeiros Sandrelli Meridiana de Fátima Ramos, Sousa Lino Bruna Maria Nepomuceno, Perez Vinícius Pietta, Sousa Eduardo Sérgio Soares, Campana Eloiza Helena, Miyajima Fábio, Carvalho-Silva Wlisses Henrique Veloso, Dejani Naiara Naiana, de Sousa Fernandes Matheus Santos, Yagin Fatma Hilal, Al-Hashem Fahaid, Elkholi Safaa M, Alyami Hanan, Souto Fabrício Oliveira
Аннотация
OBJECTIVES: This study was performed to identify predictive markers of worse outcomes in patients with severe COVID-19 in an intensive care unit.
METHODS: Sixty patients with severe COVID-19, hospitalized in the Intensive Care Unit (ICU) between March and July 2021, were stratified into two groups according to the outcome survivors and non-survivors. After admission to the ICU, blood samples were collected directly for biomarker analysis. Routine hematological and biochemical biomarkers, as well as serum levels of cytokines, chemokines, and immunoglobulins, were investigated.
RESULTS: Lymphopenia, neutrophilia, and thrombocytopenia were more pronounced in non-surviving patients, while the levels of CRP, AST, creatinine, ferritin, AST, troponin I, urea, magnesium, and potassium were higher in the non-surviving group than the survival group. In addition, serum levels of IL-10, CCL2, CXCL9, and CXCL10 were significantly increased in patients who did not survive. These changes in the biomarkers evaluated were associated with increased mortality in patients with severe COVID-19.
CONCLUSION: The present study confirmed and expanded the validity of laboratory biomarkers as indicators of mortality in severe COVID-19.
METHODS: Sixty patients with severe COVID-19, hospitalized in the Intensive Care Unit (ICU) between March and July 2021, were stratified into two groups according to the outcome survivors and non-survivors. After admission to the ICU, blood samples were collected directly for biomarker analysis. Routine hematological and biochemical biomarkers, as well as serum levels of cytokines, chemokines, and immunoglobulins, were investigated.
RESULTS: Lymphopenia, neutrophilia, and thrombocytopenia were more pronounced in non-surviving patients, while the levels of CRP, AST, creatinine, ferritin, AST, troponin I, urea, magnesium, and potassium were higher in the non-surviving group than the survival group. In addition, serum levels of IL-10, CCL2, CXCL9, and CXCL10 were significantly increased in patients who did not survive. These changes in the biomarkers evaluated were associated with increased mortality in patients with severe COVID-19.
CONCLUSION: The present study confirmed and expanded the validity of laboratory biomarkers as indicators of mortality in severe COVID-19.